Most patients with acute deep venous thrombosis (DVT) are treated with systemic anticoagulation. 1 Anticoagulation alone leaves thrombus in situ and relies on endogenous fibrinolytic activity to recanalize the vein. If the body effectively lyses the clot early in the course of the disease, venous patency is restored and valve function can be preserved. 2 Furthermore, those who successfully lyse their clot are less likely to develop recurrent DVT than patients with persistent thrombus. [3] [4] [5] Iliofemoral DVT is associated with more severe acute symptoms and a high risk of postthrombotic syndrome. [6] [7] [8] [9] Postthrombotic syndrome is a debilitating condition that diminishes quality of life 10 and often worsens over time. The most severe postthrombotic morbidity is found in patients who have had thrombosis of their iliofemoral venous segment. [6] [7] [8] [9] Additionally, the risk of recurrent venous thromboembolism for patients with iliofemoral DVT is significantly higher than patients with infrainguinal DVT, 11 further escalating the likelihood and severity of their postthrombotic morbidity. 7, 12 Strategies of thrombus removal have been selectively offered to patients with extensive DVT in an attempt to reduce postthrombotic morbidity. Catheter-directed thrombolysis (CDT) has evolved as the management strategy of choice if thrombus removal is desired. Observational studies have demonstrated early success rates in the 70% to 90% range. [13] [14] [15] [16] Avoidance of postthrombotic morbidity is the goal of any strategy of thrombus removal, yet it has not been objectively measured by validated outcome instruments in studies published to date. As there is often a range of thrombus clearance, it would be instructive to know if the degree of lysis (or the amount of residual thrombus) at the completion of CDT or pharmacomechanical thrombolysis correlates with postthrombotic morbidity.
The purpose of this study was to objectively assess the postthrombotic outcome of patients treated with catheter- 
METHODS
Seventy-one consecutive patients with symptomatic acute DVT involving the iliofemoral venous segment, with or without involvement of the vena cava or infrainguinal segments, who were treated with CDT and/or pharmacomechanical thrombolysis, form the basis of this study. All patients were ambulatory, had a life expectancy of at least 2 years, and did not have an absolute contraindication to thrombolytic therapy. Three patients had known ipsilateral chronic venous disease before their acute iliofemoral DVT. This study was approved by the institutional review board and all patients signed an informed consent. All patients were treated within 20 days of symptom onset, with a mean of 4.5 days (range, 2-20 days) of onset.
DVT was initially diagnosed with a duplex ultrasound scan and confirmed with ascending phlebography. Access for CDT was obtained with ultrasound scan guidance into the ipsilateral popliteal vein, common femoral vein, and/or posterior tibial vein, depending on the location and extent of thrombosis. A pretreatment vena cavogram was performed in all patients to assess whether thrombus involved the vena cava. If the vena cava contained nonocclusive, free-floating thrombus, a vena caval filter was placed before catheter-based intervention. Otherwise, optional vena caval filters were used at the discretion of the interventionalist.
After confirmatory phlebography, the thrombosed venous segments were traversed with a 0.35-inch guidewire. Multiside-hole catheters (UniFuse; AngioDynamics, Latham, NY) were used for drip infusion of the lytic agents, and the Trellis (Covidien, Santa Clara, Calif), AngioJet (Medrad, Minneapolis, Minn), and EKOS Lysus (EKOS Corp, Bothell, Wash) catheters were used for pharmacomechanical thrombolysis. Before the availability of pharmacomechanical techniques, CDT with drip infusion was used. When pharmacomechanical techniques became available, these were used initially. If thrombus remained after pharmacomechanical treatment, CDT was then performed to lyse residual thrombus.
Patients were treated with recombinant tissue plasminogen activator (rt-PA) at a dose of 1 to 2 mg/hour depending on the volume of thrombus and the number of catheters used. In patients who had multiple catheters (ie, popliteal and posterior tibial access or those treated for bilateral DVT), a dose of 1.5 to 2 mg/hour was used. The rt-PA was infused at a concentration of 1 mg/50 mL to 1 mg/100 mL, and treatment duration ranged from 1.5 to 94 hours (mean, 37 hours).
Serial phlebography was obtained to monitor thrombus resolution after each run of the Trellis and AngioJet catheters and after every 12 to 16 hours of thrombolysis, with either drip infusion or the EKOS catheter. After lysis, areas of infrainguinal (femoral vein) venous stenoses were dilated with balloon catheters, and iliac vein stenoses were treated with venoplasty and stenting to provide unobstructed venous drainage from the common femoral vein into the vena cava. Common iliac veins were treated with 14-to 16-mm stents, with a portion of the stent adjacent to the flow divider extending into the vena cava and external iliac veins with 12-to 14-mm stents. If a stent was extended into the common femoral vein, it was kept cephalad to the saphenofemoral junction. Stents were not used in infrainguinal veins.
The posttreatment phlebogram (after lysis, balloon dilation, and stenting) was analyzed to determine the amount of residual clot compared to the pretreatment phlebogram using a modification of the venous scoring method described by Mewissen et al 13 and reported by Martinez et al. 17 Briefly, nine venous segments (inferior vena cava, common iliac, external iliac, common femoral, proximal femoral, distal femoral, popliteal, tibial, and profunda femoris veins) were evaluated and scored as follows: 0, thrombus-free (normal) segment; (1) 1% to 49% luminal reduction by thrombus and/or stenosis; (2) 50% to 99% luminal reduction; and (3) occluded. The percent of clot lysed was calculated by subtracting the posttreatment thrombus score from the pretreatment thrombus score and dividing by the pretreatment score. The physicians interpreting the phlebograms were blinded to the clinical outcomes of the patients. The physicians performing the clinical evaluation of the patients were blinded to the phlebographic results.
After catheter-based intervention, patients were anticoagulated with intravenous unfractionated heparin or lowmolecular-weight heparin and converted to warfarin to a target international normalized ratio of 2.5. The duration of anticoagulation was in accordance with the American College of Chest Physicians' guidelines 1 at a minimum, with many extended beyond 1 year. All patients were prescribed 30 to 40 mm Hg ankle-gradient compression stockings and were instructed to wear them from the time they got out of bed in the morning to the time they returned to bed at night.
Patients were examined as part of a systematic follow-up in which they returned at 2 weeks, 1 month, 3 months, 6 months, and 12 months postdischarge, and every 6 months thereafter. The reported outcomes are from their last encounter. Patients' CEAP clinical classification and Villalta scores were recorded. The CEAP clinical classification system is based on clinical classification, etiology, anatomical distribution, and pathophysiology of venous disease. 18 This study focused on the clinical class of the patient: C0, no evidence of venous disease; C1, reticular veins; C2, varicose veins; C3, edema; C4, pigmentation; C5, healed venous ulcers; and C6, active venous ulcer.
The Villalta scale consists of five patient-related venous symptoms (pain, cramps, heaviness, paresthesia, and pruritus) and six clinician-assessed physical signs (pretibial edema, skin induration, hyperpigmentation, venous ectasia, redness, and pain during calf compression), which are rated on a four-point scale: 0, none; 1, mild; 2, moderate; and 3, severe. Points are summed to produce a total score (range, 0-33). Patients were classified as having postthrombotic syndrome if their score was Ն5 or if a venous ulcer was present in a leg with previous DVT. The postthrombotic syndrome is classified as mild if the Villalta score is 5 to 9, moderate if the score is 10 to 14, and severe if the score is Ն15 or if a venous ulcer is present. 19 The Villalta scale has been validated and is reported to be a reliable method of identifying and quantifying the postthrombotic syndrome. 19 After analysis of the entire patient cohort, patients were divided into two groups based on their percentage of clot lysis-group 1 were patients who had Յ50% residual clot, and group 2 were those with Ͼ50% residual clot-to determine if there was a difference in group-related outcomes. To evaluate if a more direct correlation existed between postthrombotic morbidity and residual thrombus, each patient's clinical classification of CEAP and Villalta scores were plotted vs residual thrombus at the completion of lytic therapy.
Statistical analysis. The t statistic test was used to test the population mean score difference between the two groups. The CEAP and Villalta scores in each group are compared using the exact Wilcoxon test statistic. The Rsquare between the outcome variable (CEAP or Villalta score) and clot lysis is based on the linear trend for 10% range of clot lysis vs the mean outcome score of the corresponding range.
RESULTS
The mean age of the patients was 45 years. Thirty-two (45%) patients were women (mean age, 35 years), and 39 were men (mean age, 52 years). Twenty-three patients had a vena cava filter inserted pretreatment. Mean duration of follow-up was 18.9 months; overall clot lysis was 79% (mean). Mean clot lysis for group 1 was 42% and mean clot lysis for group 2 was 85%.
Sixty-four patients completed the CEAP and Villalta analyses. Three patients known to have chronic venous disease before their DVT were considered outliers and were excluded from this analysis. Three other patients died and one patient was lost to follow-up.
At follow-up, the mean CEAP clinical classification was 1.3 and the mean Villalta score was 3.81 for all patients. Group 1 had a median CEAP clinical classification score of 1 and group 2 had a median score of 4 (P ϭ .025). The mean Villalta scores for group 1 and group 2 were 2.21 and 7.13, respectively (P ϭ .0032; Table 1) . Fig 1 plots the CEAP clinical classification score vs percent of residual thrombus for each patient, demonstrating a direct linear correlation of CEAP clinical classification score at follow-up with residual thrombus (R 2 ϭ .74; P ϭ .0014). Fig 2 plots the Villalta score vs residual thrombus for each patient, illustrating a direct linear correlation of Villalta score with lytic success (R 2 ϭ .61; P ϭ .0032). A 10% regression trend was used; for every 10% increase in clot lysis, there was a decrease in the Villalta score of 1.33. Patients who had Ն90% lysis had few clinical findings and only three had a Villalta score Ն5, indicating that 15 of 18 (83%) were free of postthrombotic symptoms, and the three patients with postthrombotic changes had mild symptoms (Villalta scores of 5 or 6).
Complications. There were five major complications resulting from CDT: three patients had major bleeding and two developed acute renal failure. One bleeding complication was a retroperitoneal hematoma occurring suddenly on postprocedural day 6 while the patient was on systemic anticoagulation. This patient required operative decompression. Two puncture site hematomas required operative decompression. Four minor bleeding complications were puncture site hematomas, requiring a 1-to 2-unit blood transfusion, and each resolved without operative decompression. Two patients who were treated for extensive iliofemoral and vena caval thrombosis developed nonoliguric acute renal failure, both of whom had treatment times exceeding 50 hours, large contrast loads, and hemoglobinuria after rheolytic pharmacomechanical thrombolysis. Both recovered normal renal function.
DISCUSSION
The results of this study demonstrate that, in patients with iliofemoral DVT treated with CDT or pharmacomechanical thrombolysis, there is a direct correlation of postthrombotic morbidity with residual thrombus at treatment end. The greater the residual thrombus after catheterdirected thrombolysis, the worse the patients' clinical classification score and the higher their Villalta score. These results demonstrate that when a high degree of clot lysis is achieved, and rethrombosis is avoided, patients have minimal sequelae of the postthrombotic syndrome. Furthermore, the implications of these observations are that physicians who embark on a strategy of thrombus removal to treat patients with extensive DVT should persist until the thrombus is removed and resist terminating treatment early, leaving a thrombus burden behind. Patients will recognize substantial benefit, as 83% patients (15 of 18) with Յ10% residual thrombus were free of postthrombotic syndrome, and only three patients with Յ10% residual thrombus had mild symptoms (Villalta scores of 5 and 6).
The CEAP classification was designed to standardize reporting of patients with venous disease by providing an accurate snapshot of their condition. While it is thought of as a categorical variable, the clinical class of CEAP is responsive to treatment, as varicose veins, edema, pigmentation, and ulceration are part of postthrombotic morbidity and their findings correlate with treatment.
The iliofemoral venous segment is the single venous outflow channel for the lower extremities. When it becomes occluded with thrombus, patients' symptoms are often severe. If iliofemoral DVT is accompanied by infrainguinal thrombosis, patients' symptoms may escalate. This causes high venous and compartment pressures acutely, 20 which often persist as chronic venous hypertension, the basic pathophysiology of postthrombotic morbidity. 21 Patients with iliofemoral DVT treated with anticoagulation alone develop severe postthrombotic morbidity. 6, 8, 9 It has been suggested that the threat of postthrombotic morbidity several years from the acute event may not be sufficient to convince patients to undergo or physicians to recommend a strategy of thrombus removal. 22 However, patients with iliofemoral DVT are continuously symptomatic. Their postthrombotic morbidity is not delayed by years, but it is generally continuous from the time of the acute event. Kahn et al 7 studied the frequency and time course of the postthrombotic syndrome in patients with acute symptomatic DVT using the Villalta scale as the outcome measure. They reported that the best independent predictor of the postthrombotic syndrome over time was a patient's 1-month symptom score. The most important predictor of severe postthrombotic morbidity was thrombosis of the common femoral or iliac veins (odds ratio, 2.23). 7 Kahn's findings are in agreement with our observations and those reported by others that iliofemoral DVT is associated with the most severe postthrombotic morbidity.
Others have shown that, in patients with proximal DVT treated with anticoagulation alone, there is a strong relationship of residual thrombus score and venous outflow resistance at 3 months. 23 Venous outflow resistance translates into venous hypertension, which is the underlying pathophysiology of chronic venous disease. These authors concluded that a lack of recanalization after the thrombotic episode is an important predictor of the postthrombotic syndrome.
Early results of two randomized trials of CDT vs anticoagulation alone have been reported. Elsharawy and Elzayat 24 calculated that they would need 30 patients to show a 50% difference in outcome with a significance level of 0.05 at a power of 90% when treating iliofemoral patients with DVT with thrombolysis. They randomized 35 patients to CDT plus anticoagulation or anticoagulation alone. At 6 months, the patency rate with thrombolysis was 72% vs 12% with anticoagulation (P Ͻ .001). Venous valve reflux was preserved in 89% of patients undergoing thrombolysis vs 59% in patients treated with anticoagulation alone (P ϭ .04).
Enden et al 25 reported preliminary results of 103 patients with iliofemoral DVT randomized to CDT or anticoagulation as part of the Catheter-directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis (CaVenT) study. Their target was to randomize 200 patients and to report the postthrombotic syndrome at 2 years. In their 6-month interim analysis of 103 patients, iliofemoral patency was found in 64% of the thrombolysis group compared to 36% of the anticoagulation group (P ϭ .004). Physiological venous obstruction was observed in 20% of the thrombolysis group vs 49% of the anticoagulation patients (P ϭ .004). Valve function did not differ between groups. Because an occluded vein cannot reflux, valve incompetence may worsen over time in the anticoagulation group if partial recanalization occurs.
A nonrandomized single-center study reported 6-year outcomes of 103 patients treated with CDT for iliofemoral DVT. 16 Eighty-two percent of the limbs had patent veins and competent valves with no evidence of skin change or venous claudication.
The studies described in the previous paragraphs used only catheter-directed drip infusion of lytic agents. Pharmacomechanical techniques seem to improve the efficacy of thrombus clearance. 26, 27 Martinez et al 17 reported a sequential experience with isolated segmental pharmacomechanical thrombolysis vs catheter-directed thrombolysis, demonstrating that the pharmacomechanical approach resulted in more efficient overall thrombus removal, with shorter treatment times and lower doses of plasminogen activator.
The use of a variety of pharmacomechanical techniques, using lower doses of rt-PA in larger volumes of fluid, correction of underlying venous lesions with veno-plasty and stenting, and improved physician experience have all contributed to improved outcomes over time. Patients are treated today more efficiently, have shorter treatment times, receive lower doses of plasminogen activators, and have better overall outcomes than patients treated years earlier.
An important but often unrecognized consequence of iliofemoral DVT is the increased risk of recurrence. Patients with iliofemoral DVT treated with anticoagulation alone have a 2.4-fold risk of recurrence during the first 3 months of therapy, which is similar in magnitude to patients with malignancy. 11 Baekgaard et al 16 found that only 6% of patients treated with CDT developed recurrence during the 6-year follow-up, suggesting that successful thrombus elimination with restoration of vein patency reduces the high recurrence rate, thereby further reducing the risk of postthrombotic morbidity.
Investigators have established the relationship of recurrence with persistent thrombus after an episode of acute proximal DVT. 4, 5 A recent systematic review using phlebographic criteria showed an inverse correlation between thrombus regression and recurrent venous thromboembolism. 28 It has been our observation that patients successfully treated with CDT have fewer recurrences than those with larger residual thrombus burdens. 29 This raises the interesting and attractive possibility that a successful strategy of thrombus removal will diminish the risk of recurrence.
Restoring patency to the thrombosed vein and preserving valve function are considered surrogate outcomes compared to objective measures of the postthrombotic syndrome. Whereas objective measures of postthrombotic morbidity are always desirable in follow-up studies, such as those reported in this article, it is reasonable to expect that serious postthrombotic morbidity will be avoided in patients with normally patent veins with functional valves.
A limitation of this study was that it was a retrospective analysis with no randomized control group of patients treated with anticoagulation alone. A number of patients were referred for treatment after failed initial therapy with anticoagulation (severe persistent pain and swelling) or failed attempts at CDT. Therefore, the outcomes observed here may not represent those expected in a nonreferral practice.
The strengths of this study were that all patients with iliofemoral DVT who were treated with CDT or pharmacomechanical thrombolysis were included in this analysis. All had complete pretreatment and posttreatment phlebography and objective evaluation of postthrombotic morbidity. The phlebographic interpretations were performed by individuals blinded to patient outcomes, and the physicians evaluating patients were blinded to the phlebographic results. This seems to be the first report of a correlation of validated outcome measures of postthrombotic morbidity with phlebographic results after a catheter-based strategy of thrombus removal.
We are hopeful that, as more information is gathered on the benefit of strategies of thrombus removal for patients with iliofemoral DVT, treatments designed to eliminate thrombus, restore patency, and preserve valve function will be adopted. This should result in less postthrombotic morbidity and improved quality of life for patients. A large, prospective, National Institutes of Health-funded study, the Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis trial, is now underway and will provide important information in this area. 30, 31 Nearly 700 patients with iliofemoral and infrainguinal DVT will be stratified by proximal extent of thrombus and randomized to CDT plus anticoagulation or anticoagulation alone. Outcomes will focus on objective measures of postthrombotic morbidity, similar to those reported in this study. The Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis trial, by its randomized and stratified study design, will help answer the important question of whether eliminating thrombus with catheter-based techniques is an important adjunct to anticoagulation in the management of patients with acute femoropopliteal and iliofemoral DVT.
Whenever possible, patients should be randomized in well-designed studies addressing whether a strategy of thrombus removal is beneficial compared with anticoagulation alone. However, in the absence of a randomized trial, current evidence suggests that eliminating thrombus from the iliofemoral system restores patency, 13, [32] [33] [34] preserves valve function, 16 improves quality of life, 35, 36 and reduces postthrombotic morbidity.
Our results show that, in patients with iliofemoral DVT treated with catheter-based techniques of thrombus removal, there is a direct correlation of postthrombotic morbidity with residual thrombus.
